α-Glucosidase Inhibitors Market Key Highlights:
- Market Size (2024): USD 929 Million
- Projected Market Size (2034): USD 1,500 Million
- CAGR (2023-2034): 4.9%
Pricing Analysis:
- Price Growth
- Regional Variations
Market Historic Sales
- Total sales volume, year-over-year growth, product categories, and market share.
Revenue Estimation
- Forecasting future revenues based on historical data, market trends, and economic indicators.
Sales by Region
- Breakdown of sales performance across different geographical areas.
Revenue by Manufacturer
- Analysis of revenue contributions from different manufacturers in the market.
α-Glucosidase Inhibitors Market Definition
α-Glucosidase inhibitors (AGIs) market is associated with the production, manufacturing, supply, and distribution of medicament aimed at inhibiting the enzyme alpha-glucosidase. This enzyme is usually involved in carbohydrate digestion in the small intestines into glucose. Furthermore, the global Type 2 diabetes population has increased, together with an understanding of the management of the disease, and thus the oral hypoglycemic agents have increased.
The diabetic population globally is anticipated to gain 1.9 % during the forecast duration. The alpha-glucosidase inhibitors are drugs that have been accepted to treat type 2 diabetes mellitus and some may use them to postpone the onset of the disease in people with impaired glucose tolerance. The use of α-glucosidase inhibitors in combination with other antidiabetic drugs improves the control of glycemia, helps to control body weight, and decreases cardiovascular risk. This can be seen as a reflection of the growing interest in individualized strategies to treat diabetes as the condition is increasingly viewed as complex. The increase in the global α-glucosidase inhibitors market is anticipated to persist alongside other therapies and breakthroughs for the generation of easier and better treatment protocols.
α-Glucosidase Inhibitors Market Segmentation:
By Type
- Acarbose
- Voglibose
- Miglitol
- Other
By Application
- Hospital and Clinic
- Pharmacy
- Other
α-Glucosidase Inhibitors Market Companies:
- Bayer
- Bluepharma
- Strides Pharma
- Sun Pharmaceutical
- Takeda
- Pfizer
- Lunan Pharma
- SUN Pharma
- Lupin Pharma
- Glenmark Pharma
- Shandong New Time Pharmaceutical
- Weiao Pharmaceutical (Sichuan)
- Zhejiang Medicine
- Cisen Pharmaceutical
- Zhejiang Jingxin Pharmaceutical
- Nanjing Hicin Pharmaceutical
- Beijing SL Pharmaceutical
- Jinri Pharmaceutical (China)
- Hangzhou East China Pharmaceutical
- Zhejiang Hisun Pharmaceutical
- CSPC Ouyi Pharmaceutical
- Luye Pharma
- Livzon Pharm
- YaoPharma.
For any questions about this dataset or to discuss customization options, please write to us at sales@statifacts.com
